Vijay S. Choksi and Shane A. Pennington —
Much of the discussion surrounding federal cannabis rescheduling has focused on what the industry stands to gain from Schedule III treatment. For operators, investors, and regulators, however, the more significant development may be something else entirely: the line federal regulators have drawn within the cannabis industry itself.
In April, the Department of Justice and Drug Enforcement Administration (“DEA”) placed Food and Drug Administration-approved marijuana products and marijuana products subject to qualifying state medical marijuana licenses in Schedule III. Marijuana outside those categories, including marijuana sold through state adult-use programs, remains in Schedule I while the broader rescheduling process continues. The same federal action also created an expedited DEA registration pathway for qualifying state medical marijuana licensees. The result is more than a scheduling change. It creates a new federal distinction between medical and adult-use cannabis at a time when many state regulatory systems have spent years moving in the opposite direction. Across the country, states have increasingly integrated medical and adult-use operations, allowing businesses to share facilities, personnel, management, and infrastructure. Federal law is now introducing a separation that many state markets were never designed to accommodate. That emerging tension between state integration and federal separation may ultimately have a greater impact on the industry than rescheduling itself.
The Distinction Is Already Producing Real-World Consequences
The practical implications of this distinction are no longer theoretical. One of the nation’s largest multi-state operators recently restructured portions of its business following medical marijuana rescheduling. By separating operations serving both medical and adult-use markets from its federally recognized medical business, the company positioned its remaining enterprise for a listing on the New York Stock Exchange. The significance of that transaction extends beyond a single public company. It demonstrates how the distinction between Schedule III medical activity and Schedule I adult-use activity can influence governance rights, accounting treatment, corporate control, and capital markets access. In effect, a business that states may view as a single cannabis enterprise was reorganized into separate components because federal law now treats those activities differently. Access to a major U.S. exchange depended not simply on operating a cannabis business, but on structuring that business in a way that made its medical operations recognizable as a distinct federally compliant enterprise. That example illustrates a broader reality. Rescheduling may create new opportunities, but capturing those opportunities may require operators to rethink organizational structures that were originally built around integrated state markets.
State Licenses Are Becoming Part of the Federal Framework
For more than a decade, state cannabis programs developed against a backdrop of federal prohibition. State regulators established licensing systems, operational requirements, ownership restrictions, security standards, and compliance frameworks largely independent of federal participation. The new framework does not displace those state structures. In many respects, it makes them more important. A qualifying state medical marijuana license now serves as the gateway to Schedule III treatment and DEA registration. The scope of federal authorization depends on the activity permitted by the underlying state license, while the continued viability of the federal registration depends upon maintaining that license. The framework also contemplates substantial reliance on state regulatory controls in areas such as security, recordkeeping, reporting, product handling, and related compliance functions. This represents a meaningful degree of federal deference to state cannabis programs. At the same time, it creates a new form of regulatory interdependence. Routine business decisions involving ownership changes, facility modifications, management arrangements, financing transactions, or operational expansions may now require analysis under both state and federal frameworks. The challenge is that those frameworks were developed for different purposes and may not always reach the same result. A state may permit related entities to share employees, technology platforms, intellectual property (“IP”), administrative services, or physical infrastructure. It may allow a vertically integrated license to authorize activities that federal regulators view as separate categories of DEA-registered conduct. What appears efficient and permissible under state law may not fit neatly within the federal registration model. The difficult questions will arise where those systems diverge.
Operational Efficiency Versus Federal Opportunity
The tension is most visible in states that deliberately integrated medical and adult-use operations. Many programs allow a single licensee to cultivate, process, transport, and distribute products for both markets using common facilities, personnel, and management structures. From the state’s perspective, integration reduces duplicative infrastructure and permits a unified regulatory approach to substantially similar products. Federal law now introduces a distinction based not primarily on the characteristics of the product, but on the regulatory channel through which it moves. That distinction creates practical challenges throughout an organization. If the medical side of the business operates within a federally recognized Schedule III framework while the adult-use side remains outside it, operators must determine where one business legally and operationally ends and the other begins. Inventory systems may identify the intended destination of a particular product, but they don’t necessarily resolve questions involving shared personnel, manufacturing equipment, IP, insurance programs, information technology systems, or centralized corporate functions.
Tax considerations present similar issues. While qualifying Schedule III medical activity may no longer be subject to limitations historically associated with Schedule I and II businesses, many operators continue to conduct medical and adult-use operations through integrated platforms. The challenge becomes less about whether a tax benefit exists and more about how expenses, personnel, and operational costs should be allocated between federally distinct lines of business.
The broader issue is structural. Businesses that spent years creating efficiencies through shared management, facilities, purchasing power, technology, branding, and capital deployment may now need to evaluate whether preserving those efficiencies limits access to the benefits created by rescheduling.
A New Layer of Complexity for M&A and Finance
The same issues extend into acquisitions, finance transactions, and corporate governance. Historically, buyers often approached regulated cannabis businesses as enterprises operating under a single federal classification. Increasingly, that assumption may no longer be accurate. A purchaser may now be acquiring a DEA-registered medical operation, an economic interest in a separately controlled adult-use business, and a collection of service agreements connecting the two. Determining the value and risk profile of such a structure requires more than confirming that licenses remain active. Diligence may increasingly focus on who controls licensed operations, where key assets are located, how shared expenses are allocated, who owns critical IP, and whether actions affecting one license or registration could impact the broader enterprise. The same concern applies to financing arrangements. Representations, covenants, and control provisions drafted for businesses operating entirely within a Schedule I environment may produce unintended consequences when applied to enterprises consisting of both federally recognized medical activity and federally prohibited adult-use operations. As the distinction between medical and adult-use activity becomes more significant, transactional documents will likely need to evolve alongside it.
Federal Deference Will Be Tested in Practice
The federal framework attempts to avoid unnecessary duplication by leveraging existing state regulatory systems. That approach is sensible. State medical marijuana programs already oversee complex systems governing product movement, facility security, inventory controls, dispensing, and regulatory reporting. The real test will be how that deference functions across dozens of state programs that differ substantially from one another. The federal government is now relying on medical cannabis regimes with different ownership standards, licensing structures, operational requirements, and enforcement histories. A state medical marijuana license may conclusively establish that particular conduct is authorized under state law, but it does not necessarily answer whether the same conduct satisfies federal regulatory, accounting, exchange-listing, tax, or treaty considerations. That tension is likely to influence more than compliance decisions. It may affect capital allocation, acquisition strategy, organizational design, and even the relative value of medical licenses themselves. Licenses that once appeared less valuable than adult-use authorizations may take on new strategic importance if they support DEA registration, differentiated tax treatment, access to institutional capital, or potential participation in U.S. exchange markets.
The Road Ahead
The most immediate consequence of rescheduling may not be a uniform reduction in federal risk. Instead, it may be the creation of new distinctions within the regulated cannabis industry itself. Medical and adult-use operations that states treated as components of a single market may now carry different federal classifications, tax consequences, financing opportunities, governance considerations, and capital-markets pathways. As a result, operators should not begin with a generic federal compliance checklist. The more important exercise is identifying where existing business models depend on integration that the federal framework may not fully recognize. For some organizations, the primary issue will be shared operations between medical and adult-use activities. For others, it will involve management arrangements, IP ownership, financing structures, real estate relationships, or other functions that sit outside the licensed entity itself.
These issues and more will be the focus of the “From State Regulation to Federal Rescheduling: Lessons Learned and the Road Ahead” panel at Blank Rome’s 10th Annual State of the Cannabis Industry Conference in Boston, Massachusetts, on October 26, 2026. The discussion will explore how lessons from state regulation are shaping the emerging federal framework and what that transition means for operators, investors, regulators, and researchers. For years, the cannabis industry focused on whether federal law would eventually accommodate state-regulated markets. Rescheduling suggests a different question may now be emerging. The issue is no longer whether federal law recognizes cannabis at all. The issue is whether federal law recognizes the integrated businesses that states spent years creating. Operators that understand that distinction early will be best positioned to capture the benefits of Schedule III treatment without sacrificing the efficiencies, control structures, and economics on which their businesses were built.
